UCHIYAMA HOLDINGS Co.,Ltd.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from UCHIYAMA HOLDINGS Co.,Ltd.'s yearly results (2023–2026), compared with Healthcare companies in Japan. Tap ? on any ratio for what it means.
What stands out
- Tangible Assets Ratio: Of every ¥100 the company owns, ¥100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 90% of Healthcare companies in Japan.
- Tangible Net Worth Ratio: Of every ¥100 of net worth, ¥100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 85% of Healthcare companies in Japan.
Where ¥100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
¥114Over the last 3 years, every ¥100 of reported profit came with ¥114 of operating cash.
Lower than 62% of Healthcare companies in Japan.
Self-Funding Ratio
1.0×Over the last 3 years its own operating cash paid for 98% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Lower than 60% of Healthcare companies in Japan.
Cash Locked Ratio
¥9For every ¥100 of sales, ¥9 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ¥8 tied up three years earlier.
Less money tied up than 62% of Healthcare companies in Japan.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 71% of Healthcare companies in Japan.
Growth Efficiency Ratio
¥26Sales grew 10% in 3 years; of every extra ¥100 of sales, ¥26 became extra profit.
Higher than 78% of Healthcare companies in Japan.
Asset Productivity Ratio
+10% / +2%In 3 years sales changed by +10% while total assets changed by +2%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
0.2×Debt due within a year is covered 0.2 times by its yearly operating cash.
Lower than 73% of Healthcare companies in Japan.
Cash Cushion Ratio
−19%Debt, after subtracting cash, equals 19% of its market value (net debt).
Lower than 73% of Healthcare companies in Japan.
Tangible Assets Ratio
100%Of every ¥100 the company owns, ¥100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 90% of Healthcare companies in Japan.
Tangible Net Worth Ratio
100%Of every ¥100 of net worth, ¥100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 85% of Healthcare companies in Japan.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
UCHIYAMA HOLDINGS Co.,Ltd. owes ¥0.53 for every ¥1 it owns. Net profit fell 86% in the year to Mar 2026.
Compared with Healthcare companies in Japan · latest annual results Mar 2026.
P/E ratio
6.4Investors pay ¥6.4 for every ¥1 of UCHIYAMA HOLDINGS Co.,Ltd.'s yearly profit, lower than 98% of Healthcare companies in Japan.
P/B ratio
0.49The share price is 0.49 times UCHIYAMA HOLDINGS Co.,Ltd.'s book value per share, lower than 97% of Healthcare companies in Japan.
Market cap
¥7.0 BThe total market value of all of UCHIYAMA HOLDINGS Co.,Ltd.'s shares at today's price (share price × number of shares), smaller than 71% of Healthcare companies in Japan. PosiCap size class: Micro Cap.
Net worth (book value)
¥14.3 BWhat UCHIYAMA HOLDINGS Co.,Ltd. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
¥739.16Net worth divided by the number of shares. The share price of ¥360.00 is 0.5 times this, which is the P/B above.
Return on equity (ROE)
7.3%UCHIYAMA HOLDINGS Co.,Ltd. earned 7.3% on its shareholders' money over the last year, higher than 51% of Healthcare companies in Japan.
Owes vs Owns
0.53×UCHIYAMA HOLDINGS Co.,Ltd. owes ¥0.53 for every ¥1 it owns (moderate), higher than 67% of Healthcare companies in Japan.
Dividend yield
2.77%UCHIYAMA HOLDINGS Co.,Ltd. pays 2.77% of its share price as dividends a year, higher than 50% of dividend-paying Healthcare companies in Japan.
Revenue growth
+2%Revenue rose 2% in the year to Mar 2026, and grew 3% a year on average over 3 years.
Profit growth
-86%Net profit fell 86% in the year to Mar 2026.
Profit margin
1.0%UCHIYAMA HOLDINGS Co.,Ltd. keeps ¥1 of every ¥100 of revenue as net profit.
Cash quality
2.3×Cash from UCHIYAMA HOLDINGS Co.,Ltd.'s business was 2.3× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
3.4×UCHIYAMA HOLDINGS Co.,Ltd.'s operating profit covered its interest costs 3.4 times in the year to Mar 2026.
Cash vs debt
Net debtUCHIYAMA HOLDINGS Co.,Ltd. had ¥1.3 B more debt than cash (net debt) at Mar 2026.
Questions
What is UCHIYAMA HOLDINGS Co.,Ltd.'s P/E ratio?
Investors pay ¥6.4 for every ¥1 of UCHIYAMA HOLDINGS Co.,Ltd.'s yearly profit, lower than 98% of Healthcare companies in Japan.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For UCHIYAMA HOLDINGS Co.,Ltd.: ¥7.0 B ÷ ¥14.3 B (31 Mar 2026) = 0.5.
What is UCHIYAMA HOLDINGS Co.,Ltd.'s return on equity?
UCHIYAMA HOLDINGS Co.,Ltd. earned 7.3% on its shareholders' money over the last year, higher than 51% of Healthcare companies in Japan.
How much does UCHIYAMA HOLDINGS Co.,Ltd. owe compared with what it owns?
UCHIYAMA HOLDINGS Co.,Ltd. owes ¥0.53 for every ¥1 it owns (moderate), higher than 67% of Healthcare companies in Japan.
Does UCHIYAMA HOLDINGS Co.,Ltd. pay a dividend?
Yes. UCHIYAMA HOLDINGS Co.,Ltd. pays 2.77% of its share price as dividends a year, higher than 50% of dividend-paying Healthcare companies in Japan.
Is UCHIYAMA HOLDINGS Co.,Ltd.'s revenue growing?
Revenue rose 2% in the year to Mar 2026, and grew 3% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.